Journal of Laboratory Physicians
Home About us Ahead of print Current issue Back issues Subscribe Instructions Contact Login 
Wide layoutNarrow layoutPrint this page  Email this page Bookmark this page Small font size Default font size Increase font size 
 
ORIGINAL ARTICLE
Year : 2017  |  Volume : 9  |  Issue : 3  |  Page : 163-169

Acylation-stimulating protein is a surrogate biomarker for acute myocardial infarction: Role of statins


Department of Pharmacology, Toxicology and Medicine, College of Medicine, Almustansiriya University, Baghdad, Iraq

Correspondence Address:
Hayder M Al-Kuraishy
Department of Pharmacology, Toxicology and Medicine, College of Medicine, Almustansiriya University, P.O. Box 14132, Baghdad
Iraq
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0974-2727.208263

Rights and Permissions

Background: Acylation-stimulating protein (ASP) is an adipokine synthesized within adipocytes environment due to adipocyte differentiation. Aim: The aim of this study was to assess changes in ASP levels in patients with acute myocardial infarction (MI) and to correlate these variations with disease variables. Subjects and Methods: A total number of 111 patients previously and currently treated with rosuvastatin or atorvastatin presented with acute MI in a Coronary Care Unit, were divided into three groups, Group A: Thirty-nine patients treated with atorvastatin, Group B: Thirty patients treated with rosuvastatin, compared to 42 patients presented with MI not previously treated with statins were enrolled in this study. ASP and troponin-I levels and lipid profile were estimated in each group. Results: The effects of atorvastatin and rosuvastatin compared to nonstatins-treated group on the anthropometric and biochemical variables in patients with acute MI showed significant difference in all biochemical and anthropometric parameters P< 0.05. Serum ASP (nmol/l) levels were higher in control patients 57.25 ± 9.15 compared to atorvastatin-treated patients 48.43 ± 7.42 and rosuvastatin-treated patients 49.33 ± 6.52 P= 0.0124. Conclusion: ASP levels are elevated in patients with acute MI and regarded as surrogate biomarker for acute MI also; therapy with statins leads to significant reduction in ASP levels compared to nonstatins-treated patients that presented with acute MI.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed221    
    Printed9    
    Emailed0    
    PDF Downloaded29    
    Comments [Add]    

Recommend this journal